Compare Orchid Pharma with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA vs AUROBINDO PHARMA - Comparison Results

ORCHID PHARMA     Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA AUROBINDO PHARMA ORCHID PHARMA/
AUROBINDO PHARMA
 
P/E (TTM) x -120.2 19.2 - View Chart
P/BV x 34.5 4.2 828.8% View Chart
Dividend Yield % 0.0 0.3 -  

Financials

 ORCHID PHARMA   AUROBINDO PHARMA
EQUITY SHARE DATA
    ORCHID PHARMA
Sep-13
AUROBINDO PHARMA
Mar-19
ORCHID PHARMA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs194830 23.4%   
Low Rs35527 6.6%   
Sales per share (Unadj.) Rs276.5333.9 82.8%  
Earnings per share (Unadj.) Rs-79.240.4 -196.3%  
Cash flow per share (Unadj.) Rs-43.551.8 -84.0%  
Dividends per share (Unadj.) Rs02.50 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs53.9237.1 22.8%  
Shares outstanding (eoy) m70.45585.91 12.0%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x0.42.0 20.4%   
Avg P/E ratio x-1.416.8 -8.6%  
P/CF ratio (eoy) x-2.613.1 -20.1%  
Price / Book Value ratio x2.12.9 74.2%  
Dividend payout %06.2 0.0%   
Avg Mkt Cap Rs m8,067397,569 2.0%   
No. of employees `0002.817.9 15.7%   
Total wages/salary Rs m2,52725,849 9.8%   
Avg. sales/employee Rs Th6,956.110,956.9 63.5%   
Avg. wages/employee Rs Th902.51,447.7 62.3%   
Avg. net profit/employee Rs Th-1,993.01,324.3 -150.5%   
INCOME DATA
Net Sales Rs m19,477195,636 10.0%  
Other income Rs m4071,553 26.2%   
Total revenues Rs m19,884197,189 10.1%   
Gross profit Rs m1,10339,519 2.8%  
Depreciation Rs m2,5196,680 37.7%   
Interest Rs m5,2272,626 199.0%   
Profit before tax Rs m-6,23631,767 -19.6%   
Minority Interest Rs m2027 73.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m511-881 -58.0%   
Tax Rs m-1257,269 -1.7%   
Profit after tax Rs m-5,58023,645 -23.6%  
Gross profit margin %5.720.2 28.0%  
Effective tax rate %2.022.9 8.8%   
Net profit margin %-28.712.1 -237.1%  
BALANCE SHEET DATA
Current assets Rs m11,014153,645 7.2%   
Current liabilities Rs m32,060120,429 26.6%   
Net working cap to sales %-108.117.0 -636.4%  
Current ratio x0.31.3 26.9%  
Inventory Days Days95135 70.2%  
Debtors Days Days3464 52.7%  
Net fixed assets Rs m29,440103,909 28.3%   
Share capital Rs m705586 120.2%   
"Free" reserves Rs m2,043138,322 1.5%   
Net worth Rs m3,800138,908 2.7%   
Long term debt Rs m9,0181,800 501.1%   
Total assets Rs m46,510264,544 17.6%  
Interest coverage x-0.213.1 -1.5%   
Debt to equity ratio x2.40 18,319.3%  
Sales to assets ratio x0.40.7 56.6%   
Return on assets %-0.89.9 -7.7%  
Return on equity %-146.917.0 -862.7%  
Return on capital %-3.723.8 -15.7%  
Exports to sales %37.949.6 76.3%   
Imports to sales %22.618.8 120.5%   
Exports (fob) Rs m7,37897,091 7.6%   
Imports (cif) Rs m4,40636,741 12.0%   
Fx inflow Rs m7,51397,316 7.7%   
Fx outflow Rs m5,64940,589 13.9%   
Net fx Rs m1,86556,727 3.3%   
CASH FLOW
From Operations Rs m1,68216,220 10.4%  
From Investments Rs m-9,860-28,768 34.3%  
From Financial Activity Rs m6,64419,191 34.6%  
Net Cashflow Rs m-1,5356,656 -23.1%  

Share Holding

Indian Promoters % 32.3 54.1 59.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.6 8.0 57.9%  
FIIs % 3.3 27.7 11.9%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 10.2 542.2%  
Shareholders   84,811 69,601 121.9%  
Pledged promoter(s) holding % 54.9 8.6 641.6%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA With:   JUBILANT PHARMOVA   PANACEA BIOTECH  WOCKHARDT  ABBOTT INDIA  FRESENIUS KABI ONCO.  

Compare ORCHID PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

March Quarter Results, Aditya Birla Sun Life AMC IPO and Buzzing Stocks Today(Pre-Open)

On Tuesday, Indian share markets witnessed volatile trading activity and ended lower.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

Top 3 Nifty ETFs to Buy Now(Fast Profits Daily)

Apr 20, 2021

In this video I tell you the three Nifty ETFs I think are the best.

11x Bankruptcy to Bluechip Stock: A Rare India Revival Story(Profit Hunter)

Apr 16, 2021

There is no stopping this 11-bagger stock from significant upside.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA SHARE PRICE


Apr 20, 2021 (Close)

TRACK ORCHID PHARMA

  • Track your investment in ORCHID PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ORCHID PHARMA - BIOCON COMPARISON

COMPARE ORCHID PHARMA WITH

MARKET STATS